Increased Cardiovascular Implantable Electronic Device Infections

By Staff Writer

October 31, 2023

Understanding the Growing Concern

Cardiovascular Implantable Electronic Devices (CIEDs) are life-saving marvels of modern medicine. However, with over 300,000 patients receiving a new CIED implantation annually in the US alone, there has been a simultaneous surge in device infections. These infections can lead to substantial morbidity, with infected patients facing over 3-fold higher mortality compared to those without infections. Moreover, the financial burden on the healthcare system is significant.

The Significance of Prompt Intervention

The efficacy of antibiotics as a standalone treatment for CIED infection is limited. These factors have the potential to result in increased rates of infection relapse and fatality. In patients diagnosed with a definite CIED infection, the recommended course of action is the comprehensive extraction of both the device and lead. Research findings indicate that conducting extractions promptly following diagnosis leads to notable reductions in 1-year mortality rates, shorter durations of hospitalisation, and a decreased frequency of physician or hospital visits.

CIED infections and early intervention

There are concerns about the lack of compliance with guidelines for removing hardware from patients with CIED infections. The goal of this analysis was to measure the number of Medicare beneficiaries with CIED-related infections. These patients had lead extraction procedures between 2007 and 2019.  Additionally, the study attempted to analyse the resulting outcomes of these interventions. The researchers discovered that the process of lead extraction was linked to a decrease in mortality rates. Furthermore, they observed that conducting lead extraction at an earlier stage was correlated with even lower mortality rates compared to delaying the procedure.

This study identifies the need for comprehensive care in managing CIED infection. This includes identifying the infection, conducting a thorough examination, starting antibiotic treatment, making appropriate referrals, and deciding if extraction is needed. The study’s results highlight the urgent need to follow care guidelines more closely. They also stress the importance of improving quality within health systems. 

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.